COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse : AlphaMedixTM (212Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints (...)
08/10/2025
AlphaMedix TM ( 212 Pb-DOTAMTATE) a satisfait l’ensemble des critères d’évaluation principaux d’efficacité lors de l’essai de phase 2, démontrant des bénéfices cliniquement significatifs chez les patients atteints de [...]
NJ-Founded MetasTx Fast-Tracks Precision Approach to Stop Prostate Cancer Spread; NCI-Backed Diagnostic in Proof-of-Concept, Next-Gen KIT Inhibitor Advancing Toward First-in-Human
07/10/2025
PITTSBURGH, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MetasTx, an early-stage biotech originally founded in New Jersey and now headquartered in Pittsburgh, announced progress on its two-part precision oncology platform designed [...]
Inventiva présentera plusieurs abstracts lors du congrès AASLD The Liver Meeting® 2025
07/10/2025
Présentation d’une comparaison entre histologie numérique et sur lame des biopsies de screening de l’étude de Phase 3 NATiV3 Présentation de pathologie numérique de données précliniques avec lanifibranor Daix (France), [...]
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
07/10/2025
Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 study Presentation of digital pathology data from preclinical studies with lanifibranor Daix (France [...]
AAVantgarde announces 3 presentations at ESGCT 2025 annual meeting
07/10/2025
MILAN, Oct. 07, 2025 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced three presentations at the [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/10/2025
VANCOUVER, British Columbia and BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, [...]
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
07/10/2025
PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and [...]
Neurona Expands Investigation of NRTX-1001 Cell Therapy into Mesial Temporal Lobe Epilepsy (MTLE) without Mesial Temporal Sclerosis (MTS)
07/10/2025
- First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events reported to date - - Data from this non-MTS cohort, together with results [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
07/10/2025
CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
07/10/2025
WEST CHESTER, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical [...]
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
07/10/2025
CUPERTINO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Triumph Steps Expands Emotional Literacy Programs to Schools Nationwide
07/10/2025
New Curriculum Empowers Students, Educators, and Families to Build Resilience and Purpose Together Miami, Florida , Oct. 07, 2025 (GLOBE NEWSWIRE) -- Triumph Steps , an emotional literacy platform trusted by [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
07/10/2025
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 07 oct. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
07/10/2025
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 40 - 2025
07/10/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 29 Septembre au 03 Octobre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 40 - 2025
07/10/2025
Aggregated presentation by day and by market Statement of transactions in own shares from September 29th to October 03rd 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the [...]
Update: Checkerspot and Huvepharma Partner to Commercialize Groundbreaking Human Milk Fat Analog
07/10/2025
Clearing a Major Technological Hurdle, Checkerspot & Huvepharma Ready to Scale Production of the Novel, Direct Analog for Human Milk Fat Alameda, Calif (USA) and Sofia (Bulgaria), Oct. 07, 2025 (GLOBE NEWSWIRE) -- [...]
Herantis Pharma presents positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease
07/10/2025
Herantis Pharma announces positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Trial meets all primary and secondary endpoints establishing a strong foundation to Phase 2 The [...]
Obesity Surgery Program Led by Dr. Mesut Caynak Expands Adoption of the ‘Caynak Technique’; SRC Master Accreditation Renewed
07/10/2025
Protocol-driven approach emphasizes system reliability, measured verification, and a 12-month structured follow-up to advance patient safety and outcomes Photo: Dr. Mesut Caynak ANTALYA, Turkey, Oct. 07, 2025 (GLOBE [...]

Pages